We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cizzle Biotechnology Holdings Plc | LSE:CIZ | London | Ordinary Share | GB00BNG2VN02 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.55 | 1.40 | 1.90 | 0.00 | 07:30:03 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 0 | -1.72M | -0.0047 | -3.30 | 5.64M |
TIDMCIZ
RNS Number : 2600E
Cizzle Biotechnology Holdings PLC
28 June 2023
28 June 2023
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Result of AGM
Cizzle Biotechnology, the UK-based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a show of hands and were passed.
The proxy votes cast in respect of the resolutions were as follows:
Resolution For Against Votes withheld Total votes % Total % votes ------------- ------------ ----- ------------ 1. To receive the Company's annual report and accounts for the year ended 31 December 2022 89,757,080 97.11 2,672,935 2.89 1,661,693 ------------- ------ ------------ ----- ------------ 2. To approve the Directors' Remuneration Report 88,827,568 96.10 3,602,447 3.90 1,661,693 ------------- ------ ------------ ----- ------------ 3. To re-appoint Allan John Syms as a Director of the Company 88,827,578 96.14 3,568,237 3.86 1,695,893 ------------- ------ ------------ ----- ------------ 4. To re-appoint PKF Littlejohn LLP as auditor of the Company 88,861,778 96.14 3,568,237 3.86 1,661,693 ------------- ------ ------------ ----- ------------ 5. To authorise the Directors to determine the auditor's remuneration 88,861,778 96.14 3,568,237 3.86 1,661,693 ------------- ------ ------------ ----- ------------ 6. Authorises the Directors to allot shares in the Company or to grant rights to subscribe for, or to convert any security into, shares in the Company 88,661,778 95.92 3,768,237 4.08 1,661,693 ------------- ------ ------------ ----- ------------ 7. Authorise the Directors to allot equity securities disapplying pre-emption rights 88,823,568 96.10 3,606,437 3.90 1 ,661,703 ------------- ------ ------------ ----- ------------ 8. That General Meetings may be called on not less than 14 days' notice 88,861,778 96.14 3,568,237 3.86 1,661,693 ------------- ------ ------------ ----- ------------
Enquiries:
Cizzle Biotechnology Holdings Via IFC Advisory plc Allan Syms (Executive Chairman) Allenby Capital Limited +44(0) 20 33285656 John Depasquale Alex Brearley Novum Securities Limited +44(0) 20 7399 9400 Colin Rowbury Jon Bellis IFC Advisory Limited +44(0) 20 3934 6630 Tim Metcalfe cizzle@investor-focus.co.uk Florence Chandler
Notes to Editors:
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGSEUFSAEDSEIM
(END) Dow Jones Newswires
June 28, 2023 07:01 ET (11:01 GMT)
1 Year Cizzle Biotechnology Chart |
1 Month Cizzle Biotechnology Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions